Noom’s shifting from coach to co-pilot.
The latest: The digital health platform launched Body Scan, an AI-powered feature tracking muscle mass for GLP-1 users.
Whole in one. Founded in 2008, Noom has raised more than $650M to scale its behavior-focused weight loss app. After restructuring last year, the company is pivoting from diet support to digital health partner.
Entering medical weight loss, Noom is adapting its lifestyle-based approach for GLP-1 takers.
- In May, it synced FitOn’s fitness library, including curated muscle-preserving workouts.
- This June, it launched an AI assistant, photo food logging, and a gamified wellness app.
- Last week, Noom expanded its healthcare team, creating modules for women’s health.
Meanwhile, after adding compounded weight loss drugs last month, it partnered with pharmacy disruptor Waltz Health for cost-effective name-brands — packaging both options for employers.
Supporting cast. GLP-1s are table stakes in telehealth — but >70% of consumers still reject the idea that drugs can replace lifestyle changes like eating well.
Still benefiting as a first-mover, hims & hers bought a compounding pharmacy for continuity, while WeightWatchers failed to capitalize after acquiring Sequence.
Rethinking outcomes, knownwell acquiring Alfie Health to boost treatment plans, and Evolt is lending its body comp tech to providers to monitor muscle-to-fat ratios among patients.
Punchline: With compounded prescriptions only viable as long as an FDA loophole remains open, Noom is securing its supply while building out tools to make the outcomes stick.